References:

1. van Hinsbergh VWM. The endothelium: vascular control of haemostasis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2001;95(2):198-201.
2. Mason R, Mohammad S, Saba H, Chuang H, Lee E, Balis J. Functions of endothelium. Pathobiology annual. 1979;9:1.
3. Galley HF, Webster NR. Physiology of the endothelium. British journal of anaesthesia. 2004;93(1):105-13.
4. Nasir NM, Thevarajah M, Yean CY. Hemoglobin variants detected by hemoglobin A1c (HbA1c) analysis and the effects on HbA1c measurements. International journal of diabetes in developing countries. 2010;30(2):86.
5. Sandoo A, van Zanten JJV, Metsios GS, Carroll D, Kitas GD. The endothelium and its role in regulating vascular tone. The open cardiovascular medicine journal. 2010;4:302.
6. Gryglewski RJ, Botting RM, Vane JR. Mediators produced by the endothelial cell. Hypertension. 1988;12(6):530-48.
7. Allen JD, Cobb FR, Gow AJ. Regional and whole-body markers of nitric oxide production following hyperemic stimuli. Free Radical Biology and Medicine. 2005;38(9):1164-9.
8. Bogle R, MacAllister R, Whitley G, Vallance P. Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? American Journal of Physiology-Cell Physiology. 1995;269(3):C750-C6.
9. Félétou M, editor The endothelium, Part I: Multiple functions of the endothelial cells--focus on endothelium-derived vasoactive mediators. Colloquium Series on Integrated Systems Physiology: From Molecule to Function; 2011: Morgan & Claypool Life Sciences.
10. Cook‐Mills JM, Deem TL. Active participation of endothelial cells in inflammation. Journal of leukocyte biology. 2005;77(4):487-95.
11. Rasche H. Haemostasis and thrombosis: an overview. European Heart Journal Supplements. 2001;3(suppl_Q):Q3-Q7.
12. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nature Reviews Immunology. 2007;7(10):803.
13. Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. International journal of vascular medicine. 2012;2012.
14. Sena CM, Pereira AM, Seiça R. Endothelial dysfunction—a major mediator of diabetic vascular disease. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2013;1832(12):2216-31.
15. Arrebola-Moreno AL, Laclaustra M, Kaski JC. Noninvasive assessment of endothelial function in clinical practice. Revista Española de Cardiología (English Edition). 2012;65(1):80-90.
16. Rubanyi G, Vanhoutte P. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. American Journal of Physiology-Heart and Circulatory Physiology. 1986;250(5):H822-H7.
17. Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vascular health and risk management. 2005;1(3):183.
18. Zhang X-y, Zhao S-P, Li X-P, Gao M, Zhou Q-C. Endothelium-dependent and -independent functions are impaired in patients with coronary heart disease. Atherosclerosis. 2000;149(1):19-24.
19. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arteriosclerosis, thrombosis, and vascular biology. 2003;23(2):168-75.
20. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. The international journal of cardiovascular imaging. 2010;26(6):631-40.
21. Ras RT, Streppel MT, Draijer R, Zock PL. Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. International journal of cardiology. 2013;168(1):344-51.
22. Xu Y, Arora RC, Hiebert BM, Lerner B, Szwajcer A, McDonald K, et al. Non-invasive endothelial function testing and the risk of adverse outcomes: a systematic review and meta-analysis. European Heart Journal–Cardiovascular Imaging. 2014;15(7):736-46.
23. Matsuzawa Y, Kwon TG, Lennon RJ, Lerman LO, Lerman A. Prognostic value of flow‐mediated vasodilation in brachial artery and fingertip artery for cardiovascular events: a systematic review and meta‐analysis. Journal of the American Heart Association. 2015;4(11):e002270.
24. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. Journal of the American College of Cardiology. 2002;39(2):257-65.
25. Allan R, Delaney C, Miller M, Spark J. A comparison of flow-mediated dilatation and peripheral artery tonometry for measurement of endothelial function in healthy individuals and patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery. 2013;45(3):263-9.
26. Kuvin JT, Patel AR, Sliney KA, Pandian NG, Sheffy J, Schnall RP, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. American Heart Journal. 2003;146(1):168-74.
27. Kovarnik T, Jerabek S, Chen Z, Wahle A, Zhang L, Dostalova G, et al. Non-invasive endothelial function assessment using digital reactive hyperaemia correlates with three-dimensional intravascular ultrasound and virtual histology-derived plaque volume and plaque phenotype. Kardiologia polska. 2016;74(12):1485.
28. Leite AR, Borges-Canha M, Cardoso R, Neves JS, Castro-Ferreira R, Leite-Moreira A. Novel Biomarkers for Evaluation of Endothelial Dysfunction. Angiology. 2020;71(5):397-410.
29. Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, et al. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. American Journal of Physiology-Heart and Circulatory Physiology. 2011;300(1):H2-H12.
30. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. Journal of the American College of Cardiology. 1995;26(5):1235-41.
31. Chouhan M, Mandloi SS, Kansal A, Jatav OP. To study the endothelial dysfunction by brachial artery flow mediated dilatation in coronary artery disease patients. 2017. 2017;4(4):7.
32. Poredos P, Jezovnik MK. Testing endothelial function and its clinical relevance. Journal of atherosclerosis and thrombosis. 2013;20(1):1-8.
33. Donald AE, Charakida M, Falaschetti E, Lawlor DA, Halcox JP, Golding J, et al. Determinants of vascular phenotype in a large childhood population: the Avon Longitudinal Study of Parents and Children (ALSPAC). European Heart Journal. 2010;31(12):1502-10.
34. Celermajer DS. Reliable endothelial function testing: at our fingertips? : Am Heart Assoc; 2008.
35. Heffernan KS, Karas RH, Patvardhan EA, Jafri H, Kuvin JT. Peripheral arterial tonometry for risk stratification in men with coronary artery disease. Clinical cardiology. 2010;33(2):94-8.
36. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes Jr DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101(9):948-54.
37. Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitra D, Ganz P. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. Journal of applied physiology. 2006;101(2):545-8.
38. Reisner Y, Lusky R, Shay-El Y, Schnall R, Herscovici S, editors. Reproducibility of endothelial function and arterial stiffness assessed using finger peripheral arterial tonometry. European Heart Journal; 2008: OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND.
39. Zhao X, Arsenault A, Lavoie KL, Meloche B, Bacon SL, editors. Tracer Kinetics of Forearm Endothelial Function: Comparison of an Empirical Method and a Quantitative Modeling Technique. Engineering in Medicine and Biology Society, 2007 EMBS 2007 29th Annual International Conference of the IEEE; 2007: IEEE.
40. Bacon SL, Meloche B, Lavoie KL, Arsenault A. Differential short-term repeated forearm hyperaemic reactivity in coronary artery disease patients compared to healthy low risk participants. International journal of molecular imaging. 2012;2012.
41. Veldhuizen van Zanten J, Meloche B, Bacon S, Stébenne P, Arsenault A, Lavoie K. Inter-observer reliability of a new method to measure endothelial function. Psychosom Med. 2006;68:A36.
42. Dupuis J, Arsenault A, Meloche B, Harel F, Staniloae C, Grégoire J. Quantitative hyperemic reactivity in opposed limbs during myocardial perfusion imaging: a new marker of coronary artery disease. Journal of the American College of Cardiology. 2004;44(7):1473-7.
43. Storch AS, Mattos JDd, Alves R, Galdino IdS, Rocha HNM. Methods of Endothelial Function Assessment: Description and Applications. International Journal of Cardiovascular Sciences. 2017;30(3):262-73.
44. Nozaki T, Sugiyama S, Koga H, Sugamura K, Ohba K, Matsuzawa Y, et al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. Journal of the American College of Cardiology. 2009;54(7):601-8.
45. Celermajer DS, Sorensen KE, Gooch V, Spiegelhalter D, Miller O, Sullivan I, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. The lancet. 1992;340(8828):1111-5.
46. Committee CDACPGE. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes; 2013.
47. Ivers NM, Jiang M, Alloo J, Singer A, Ngui D, Casey CG, et al. Diabetes Canada 2018 clinical practice guidelines: Key messages for family physicians caring for patients living with type 2 diabetes. Canadian Family Physician. 2019;65(1):14-24.
48. Organization WH. Global report on diabetes: World Health Organization; 2016.
49. Canadian Task Force on Preventive Health C. Recommendations on screening for type 2 diabetes in adults. CMAJ : Canadian Medical Association Journal. 2012;184(15):1687-96.
50. Association CD. Diabetes Facts The university of british columbia [Available from: http://ok-smallsteps.sites.olt.ubc.ca/health-care-providers/diabetes-facts/.
51. Canada PHAo. Diabetes in Canada: facts and figures from a public health perspective. Public Health Agency of Canada Ottawa, ON; 2011.
52. Fox CS, Coady S, Sorlie PD, D’Agostino RB, Pencina MJ, Vasan RS, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation. 2007;115(12):1544-50.
53. Tooke JE. Microvasculature in diabetes. Cardiovascular research. 1996;32(4):764-71.
54. Canada d. New diabetes rates released with urgent plea for governments to implement national diabetes strategy Diabetes Canada2019.
55. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes care. 2005;28(4):956-62.
56. Denny K, Lawand C, Perry SD. Compromised wounds in Canada. Healthcare Quarterly. 2014;17(1).
57. Wallinga D. Agricultural policy and childhood obesity: a food systems and public health commentary. Health Affairs. 2010;29(3):405-10.
58. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes care. 2010;33(Suppl 1):S62.
59. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomarker insights. 2016;11:BMI. S38440.
60. Sicard DA, Taylor JR. Comparison of point-of-care HbA1c test versus standardized laboratory testing. Annals of Pharmacotherapy. 2005;39(6):1024-8.
61. Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W, Bullard KM, et al. A1C Level and Future Risk of Diabetes: A Systematic Review. Diabetes Care. 2010;33(7):1665-73.
62. Alice Y.Y. Cheng MD F, Tracy Barnes MA, MJ. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2016 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.: diabetes canada; 2016.
63. American Diabetes A. Standards of Medical Care in Diabetes—2011. Diabetes Care. 2011;34(Suppl 1):S11-S61.
64. Ronald Goldenberg MD F, FACE Zubin Punthakee MD, MSc, FRCPC. Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee; 2016.
65. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes. 1997;46(Supplement 2):S9-S13.
66. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annual review of medicine. 1993;44(1):121-31.
67. Basha B, Samuel SM, Triggle CR, Ding H. Endothelial dysfunction in diabetes mellitus: possible involvement of endoplasmic reticulum stress? Experimental diabetes research. 2012;2012.
68. Maiuolo J, Gliozzi M, Musolino V, Carresi C, Nucera S, Macrì R, et al. The role of endothelial dysfunction in peripheral blood nerve barrier: molecular mechanisms and pathophysiological implications. International journal of molecular sciences. 2019;20(12):3022.
69. Halimi J-M, Bonnet F, Lange C, Balkau B, Tichet J, Marre M, et al. Urinary albumin excretion is a risk factor for diabetes mellitus in men, independently of initial metabolic profile and development of insulin resistance. The DESIR Study. Journal of hypertension. 2008;26(11):2198-206.
70. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis 1. The American journal of medicine. 1999;107(1):85-97.
71. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. Jama. 2004;291(16):1978-86.
72. Ceriello A BN, Crescentini A, Motz E, Lizzio S, Russo A, Ezsol Z, Tonutti L, Taboga C. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. European journal of clinical investigation. 1998 Apr 28(4):329-33.
73. Shi Y, Vanhoutte PM. Reactive oxygen‐derived free radicals are key to the endothelial dysfunction of diabetes. Journal of diabetes. 2009;1(3):151-62.
74. Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation. 2002;105(5):576-82.
75. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Current opinion in lipidology. 2001;12(4):383-9.
76. Tierney ESS, Newburger JW, Gauvreau K, Geva J, Coogan E, Colan SD, et al. Endothelial pulse amplitude testing: feasibility and reproducibility in adolescents. The Journal of pediatrics. 2009;154(6):901-5.
77. Punthakee Z, Goldenberg R, Katz P. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Canadian journal of diabetes. 2018;42:S10-S5.
78. Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, et al. The assessment of endothelial function: from research into clinical practice. Circulation. 2012;126(6):753-67.
79. Esper RJ, Nordaby RA, Vilariño JO, Paragano A, Cacharrón JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. Cardiovascular diabetology. 2006;5(1):4.
80. Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible? Journal of the American College of Cardiology. 1997;30(2):325-33.
81. Cnop M, Welsh N, Jonas J-C, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54(suppl 2):S97-S107.
82. Tooke J, Hannemann M. Adverse endothelial function and the insulin resistance syndrome. Journal of internal medicine. 2000;247(4):425-31.
83. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. The Journal of clinical investigation. 1996;97(11):2601-10.
84. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circulation research. 2010;106(8):1319-31.
85. Lorbeer R, Empen K, Dörr M, Arndt M, Schipf S, Nauck M, et al. Association between glycosylated haemoglobin A1c and endothelial function in an adult non-diabetic population. Atherosclerosis. 2011;217(2):358-63.
86. Rodriguez CJ, Miyake Y, Grahame-Clarke C, Di Tullio MR, Sciacca RR, Boden-Albala B, et al. Relation of plasma glucose and endothelial function in a population-based multiethnic sample of subjects without diabetes mellitus. The American journal of cardiology. 2005;96(9):1273-7.
87. Freeman DJ, Norrie J, Sattar N, Neely RDG, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103(3):357-62.
88. Cominacini L, Garbin U, Pasini AF, Campagnola M, Davoli A, Foot E, et al. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes. 1998;47(1):130-3.
89. Caballero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism. 2003;52(2):173-80.
90. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of internal medicine. 2009;151(4):W-65-W-94.
91. Penson D, Krishnaswami S, Jules A. Newcastle–Ottawa Quality Assessment Form for Cohort Studies; 2012. 2018.
92. Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle–Ottawa scale and the RTI item bank. Clinical epidemiology. 2014;6:359.
93. Ostlund E, Al-Nashi M, Hamad RR, Larsson A, Eriksson M, Bremme K, et al. Normalized endothelial function but sustained cardiovascular risk profile 11 years following a pregnancy complicated by preeclampsia. Hypertension Research. 2013;36(12):1081-7.
94. Rossi R, Cioni E, Nuzzo A, Origliani G, Modena MG. Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women. Diabetes Care. 2005;28(3):702-7.
95. Joris PJ, Plat J, Kusters Y, Houben A, Stehouwer CDA, Schalkwijk CG, et al. Diet-induced weight loss improves not only cardiometabolic risk markers but also markers of vascular function: a randomized controlled trial in abdominally obese men. American Journal of Clinical Nutrition. 2017;105(1):23-31.
96. Bredella MA, Gerweck AV, Lin E, Landa MG, Torriani M, Schoenfeld DA, et al. Effects of GH on Body Composition and Cardiovascular Risk Markers in Young Men With Abdominal Obesity. Journal of Clinical Endocrinology & Metabolism. 2013;98(9):3864-72.
97. Meigs JB, O’Donnell CJ, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes. 2006;55(2):530-7.
98. Odegaard AO, Jacobs DR, Sanchez OA, Goff DC, Reiner AP, Gross MD. Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes. Cardiovascular Diabetology. 2016;15(1):51.
99. Thorand B, Baumert J, Chambless L, Meisinger C, Kolb H, Doring A, et al. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arteriosclerosis, thrombosis, and vascular biology. 2006;26(2):398-405.
100. Olausson J, Daka B, Hellgren MI, Larsson CA, Petzold M, Lindblad U, et al. Endothelin-1 as a predictor of impaired glucose tolerance and type 2 diabetes--A longitudinal study in the Vara-Skovde Cohort. Diabetes research and clinical practice. 2016;113:33-7.
101. Huth C, Bauer A, Zierer A, Sudduth-Klinger J, Meisinger C, Roden M, et al. Biomarker-defined pathways for incident type 2 diabetes and coronary heart disease-a comparison in the MONICA/KORA study. Cardiovasc Diabetol. 2020;19(1):32.
102. Amudha K, Choy AM, Mustafa MR, Lang CC. Short-Term Effect of Atorvastatin on Endothelial Function in Healthy Offspring of Parents with Type 2 Diabetes Mellitus. Cardiovascular Therapeutics. 2008;26(4):253-61.
103. Goldfine AB, Beckman JA, Betensky RA, Devlin H, Hurley S, Varo N, et al. Family history of diabetes is a major determinant of endothelial function. Journal of the American College of Cardiology. 2006;47(12):2456-61.
104. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999;48(9):1856-62.
105. Anastasiou E, Lekakis JP, Alevizaki M, Papamichael CM, Megas J, Souvatzoglou A, et al. Impaired endothelium-dependent vasodilatation in women with previous gestational diabetes. Diabetes care. 1998;21(12):2111-5.
106. Kautzky-Willer A, Fasching P, Jilma B, Waldhausl W, Wagner O. Persistent elevation and metabolic dependence of circulating E-selectin after delivery in women with gestational diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism. 1997;82(12):4117-21.
107. Knock GA, McCarthy AL, Lowy C, Poston L. Association of gestational diabetes with abnormal maternal vascular endothelial function. BJOG: An International Journal of Obstetrics & Gynaecology. 1997;104(2):229-34.
108. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation. 2000;101(15):1780-4.
109. Henry RMA, Ferreira I, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, et al. Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not: The Hoorn Study. Atherosclerosis. 2004;174(1):49-56.
110. Voidonikola PT, Stamatelopoulos KS, Alevizaki M, Kollias GE, Zakopoulos NA, Lekakis JP, et al. The association between glycemia and endothelial function in nondiabetic individuals: the importance of body weight. Obesity. 2008;16(12):2658-62.
111. Group UPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The lancet. 1998;352(9131):837-53.
112. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. New England Journal of Medicine. 2010;362(9):800-11.
113. Cui M, Cui R, Liu K, Dong J-Y, Imano H, Hayama-Terada M, et al. Associations of tobacco smoking with impaired endothelial function: the Circulatory Risk in Communities Study (CIRCS). Journal of atherosclerosis and thrombosis. 2018:42150.
114. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. The Journal of clinical investigation. 1994;94(3):1172-9.
115. Zoccali C, Puntorieri E. Type-2 diabetes and endothelial dysfunction: exploring the road to disease in the reverse direction. Journal of hypertension. 2008;26(11):2096-100.
116. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. Journal of the American College of Cardiology. 2001;37(5):1344-50.
117. Group DPPR. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England journal of medicine. 2002;346(6):393-403.
118. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clinical science. 2005;109(2):143-59.
119. van den Oever IA, Raterman HG, Nurmohamed MT, Simsek S. Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators of inflammation. 2010;2010.
120. Katz SD, Hryniewicz K, Hriljac I, Balidemaj K, Dimayuga C, Hudaihed A, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005;111(3):310-4.
121. Stehouwer CD, Gall M-A, Twisk JW, Knudsen E, Emeis JJ, Parving H-H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51(4):1157-65.
122. von Scholten BJ, Reinhard H, Hansen TW, Schalkwijk CG, Stehouwer C, Parving H-H, et al. Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria. Journal of Diabetes and its Complications. 2016;30(2):248-55.
123. Seon CS, Min KW, Lee SY, Nho KW, Park SH, Koo BK, et al. Cardiovascular Risk Assessment with Vascular Function, Carotid Atherosclerosis and the UKPDS Risk Engine in Korean Patients with Newly Diagnosed Type 2 Diabetes. Diabetes & metabolism journal. 2011;35(6):619-27.
124. Raitakari OT, Adams MR, McCredie RJ, Griffiths KA, Celermajer DS. Arterial Endothelial Dysfunction Related to Passive Smoking Is Potentially Reversible in Healthy Young Adults. Annals of Internal Medicine. 1999;130(7):578-81.
125. Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. The Journal of clinical investigation. 1996;97(8):1989-94.
126. Sena CM, Pereira AM, Seiça R. Endothelial dysfunction — A major mediator of diabetic vascular disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2013;1832(12):2216-31.
127. Dhananjayan R, Koundinya KS, Malati T, Kutala VK. Endothelial dysfunction in type 2 diabetes mellitus. Indian Journal of Clinical Biochemistry. 2016;31(4):372-9.
128. Jansson PA. Endothelial dysfunction in insulin resistance and type 2 diabetes. Journal of internal medicine. 2007;262(2):173-83.
129. Sjöholm Å, Nyström T. Endothelial inflammation in insulin resistance. The Lancet. 2005;365(9459):610-2.
130. McCrea CE, Skulas-Ray AC, Chow M, West SG. Test–retest reliability of pulse amplitude tonometry measures of vascular endothelial function: implications for clinical trial design. Vascular medicine. 2012;17(1):29-36.